Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Yubo International Biotech Limited (YBGJ) had Consolidated Net Income/Loss of $-0.27M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-0.25M |
|
-- |
|
-- |
|
$0.24M |
|
$-0.24M |
|
$-0.03M |
|
$-0.27M |
|
$-0.27M |
|
$-0.27M |
|
$-0.27M |
|
|
Consolidated Net Income/Loss |
$-0.27M |
$-0.27M |
|
$-0.24M |
|
$-0.24M |
|
170.42M |
|
170.42M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$0.58M |
|
$0.02M |
|
$0.09M |
|
$0.67M |
|
$3.33M |
|
-- |
|
-- |
|
$3.33M |
|
$-2.66M |
|
$-2.70M |
|
$-2.66M |
|
170.42M |
|
| Cash Flow Statement Financials | |
$-0.29M |
|
-- |
|
$0.29M |
|
$0.01M |
|
$0.01M |
|
$0.00M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.18 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
10.12% |
|
9.97% |
|
-39.97% |
|
10.12% |
|
$-0.02 |
|
$-0.00 |
|
$-0.00 |
|